Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;20(12):O1117-20.
doi: 10.1111/1469-0691.12714. Epub 2014 Dec 12.

Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance

D van Duin  1 , E D Cober, S S Richter, F Perez, M Cline, K S Kaye, R C Kalayjian, R A Salata, S R Evans, V G Fowler Jr, R A Bonomo
Affiliations

Tigecycline therapy for carbapenem-resistant Klebsiella pneumoniae (CRKP) bacteriuria leads to tigecycline resistance

D van Duin et al. Clin Microbiol Infect. 2014 Dec.

Abstract

Carbapenem-resistant Klebsiella pneumoniae (CRKP) is an increasing global threat. Here, we describe the prevalence and impact of tigecycline use in a cohort of patients with CRKP bacteriuria nested within a multicentre, prospective study. In the 21-month study period, 260 unique patients were included. Tigecycline was given to 80 (31%) patients. The use of tigecycline during the index hospitalization was significantly associated with the subsequent development of tigecycline resistance in the same patient (OR, 6.13; 95% CI, 1.15-48.65; p 0.03). In conclusion, the use of tigecycline with CRKP bacteriuria is common, and is associated with the subsequent development of tigecycline resistance.

Keywords: Carbapenem-resistant Enterobacteriaceae; multidrug resistance; urinary tract infection.

PubMed Disclaimer

Figures

Figure
Figure
Diagram outlining patient flow throughout the study. CRKP carbapenem resistant Klebsiella pneumoniae. UTI urinary tract infection. CRKP readmission is defined as any readmission during which CRKP was again isolated from a clinical culture from any anatomical site.
See this image and copyright information in PMC

Comment in

References

    1. Braykov NP, Eber MR, Klein EY, Morgan DJ, Laxminarayan R. Trends in resistance to carbapenems and third-generation cephalosporins among clinical isolates of klebsiella pneumoniae in the united states, 1999–2010. Infect Control Hosp Epidemiol. 2013;34:259–268. - PubMed
    1. van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant enterobacteriaceae: A review of treatment and outcomes. Diagn Microbiol Infect Dis. 2013;75:115–120. - PMC - PubMed
    1. Sader HS, Farrell DJ, Flamm RK, Jones RN. Tigecycline activity when tested against bacterial strains from united states medical centers: Variation in potency and spectrum since approval for clinical use (2006–2012) Antimicrob Agents Chemother. 2014
    1. Huang TD, Berhin C, Bogaerts P, Glupczynski Y. In vitro susceptibility of multidrug-resistant enterobacteriaceae clinical isolates to tigecycline. J Antimicrob Chemother. 2012;67:2696–2699. - PubMed
    1. Lopez-Camacho E, Gomez-Gil R, Tobes R, et al. Genomic analysis of the emergence and evolution of multidrug resistance during a klebsiella pneumoniae outbreak including carbapenem and colistin resistance. J Antimicrob Chemother. 2014;69:632–636. - PubMed

Publication types

MeSH terms

Associated data